Preliminary data from phase II EDGE-Gastric study demonstrate promising ORR and six-month PFS results

ASTRO publishes first guideline focused on radiation therapy for gastric cancer

A clinical guideline from the American Society for Radiation Oncology is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration with systemic therapy, and treatment delivery.

December 05, 2025

Vol.51 No.44

Clinical Roundup

Imfinzi-based regimen reduced the risk of death in early gastric cancer vs. chemotherapy alone

Perioperative treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival versus chemotherapy alone, according to MATTERHORN phase III trial results.

October 24, 2025

Vol.51 No.39

Drugs & Targets

FDA grants priority review for Imfinzi in gastric and GEJ cancer

Imfinzi (durvalumab) has been accepted and granted Priority Review by the FDA for the treatment of patients with resectable, early-stage, and locally advanced (stages 2, 3, 4a) gastric and gastroesophageal junction cancers.

August 01, 2025

Vol.51 No.30

Drugs & Targets

Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer

Alligator Bioscience on May 26 announced that the European Commission granted orphan drug designation to HLX22, an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 is being developed by Shanghai Henlius Biotech, Inc. under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator.

May 30, 2025

Vol.51 No.21

Drugs & Targets

FDA approves Tevimbra + chemo for first-line treatment of gastric and GEJ cancers

FDA approved Tevimbra (tislelizumab-jsgr) in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (≥1).

January 10, 2025

Vol.51 No.01

Drugs & Targets

LINDIS Biotech signs licensing agreement with Pharmanovia for the commercialization of catumaxomab

Lindis Biotech GmbH announced a licensing agreement with global pharmaceutical company Pharmanovia for catumaxomab, for the treatment of malignant ascites.

November 22, 2024

Vol.50 No.44

Preliminary data from phase II EDGE-Gastric study demonstrate promising ORR and six-month PFS results

YOU MAY BE INTERESTED IN

ASTRO publishes first guideline focused on radiation therapy for gastric cancer

Imfinzi-based regimen reduced the risk of death in early gastric cancer vs. chemotherapy alone

FDA grants priority review for Imfinzi in gastric and GEJ cancer

Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer

FDA approves Tevimbra + chemo for first-line treatment of gastric and GEJ cancers

LINDIS Biotech signs licensing agreement with Pharmanovia for the commercialization of catumaxomab

Renew today!

Subscriber content

Never miss an issue!

Login